From Nasdaq: 2025-04-01 16:15:00

Shares of Hims & Hers Health (NYSE: HIMS) rose 5.25% after announcing plans to sell weight loss drug Zepbound on its platform. The company will offer branded versions of Eli Lilly’s tirzepatide and biosimilar versions of Novo Nordisk’s liraglutide, joining competitors Teladoc and LifeMD in offering Zepbound. Hims & Hers previously offered compounded versions of semaglutide, but had to stop due to FDA regulations. The company’s revenue was impacted, but the new offerings should help. However, there are valuation concerns to consider before investing.

Missed out on successful stocks? Our analysts have a “Double Down” stock recommendation for potentially lucrative opportunities. Companies like Nvidia, Apple, and Netflix have seen significant returns if invested when the recommendation was made. Currently, there are alerts for three companies with promising growth potential. Check out the details before it’s too late.



Read more at Nasdaq: Why Hims & Hers Health Stock Soared Tuesday